Sun Pharmaceutical Recalls Doxycycline Capsules Due to Manufacturing Deviations
Sun Pharmaceutical Industries is recalling 624 bottles of Doxycycline Capsules, 75 mg, because they were not manufactured under Current Good Manufacturing Practice conditions.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II. The source text does not report any illnesses, injuries, or specific contamination, indicating a theoretical risk associated with manufacturing deviations rather than a confirmed high-risk pathogen or injury event.
Plain-English summary
Sun Pharmaceutical Industries, Inc. is recalling 624 bottles of Doxycycline Capsules, USP, 75 mg, 100-count bottles. The product is prescription-only and was distributed nationwide in the USA. The specific lot number is AA39490 with an expiration date of 03/2021.
The recall was initiated because the doxycycline capsules were not manufactured under Current Good Manufacturing Practice (CGMP) conditions. The capsules were manufactured by Ohm Laboratories Inc. in New Brunswick, NJ, and distributed by Sun Pharmaceutical Industries, Inc. in Cranbury, NJ.
Consumers and healthcare providers should stop using the affected product and return it to the pharmacy or point of purchase. The recall is classified as Class II by the FDA.
The recalled product
- Product
- DOXYCYCLINE (DOXYCYCLINE)
- Brand
- DOXYCYCLINE
- Manufacturer
- Sun Pharmaceutical Industries, Inc.
- Category
- Drug — Prescription Antibiotic
- Hazard
- Affected units
- 624
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: AA39490
- Exp 03/2021
UPCs (1)
- 0363304614015
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Sun Pharmaceutical Industries, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · DOXYCYCLINE
- ModerateDoxycycline hyclate tablets recalled after stability testing failed dissolution specifications
FDA (Drugs) · 2025-10-15
- ModerateDoxycycline Capsules Recalled Due to Temperature Storage Deviation
FDA (Drugs) · 2024-01-03
- ModerateDoxycycline Capsules Recalled for Temperature Control Deviation
FDA (Drugs) · 2022-06-15
- ModeratePD-Rx Recalls Doxycycline Hyclate Tablets for Failed Dissolution Specifications
FDA (Drugs) · 2020-06-03
- SevereSun Pharmaceutical Recalls Doxycycline Capsules Due to Manufacturing Deviations
FDA (Drugs) · 2020-03-25
Same manufacturer · Sun Pharmaceutical Industries, Inc.
See all →- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- HighPerampanel Prescription Tablets Recalled for Labeling Mix-up
FDA (Drugs) · 2026-07-01
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- SevereDoxorubicin liposome injection vials contain glass particulate matter
FDA (Drugs) · 2026-06-17
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19